

\$28M Philly Xarelto Verdict Ripe For Reversal, Attys Say

Wednesday, December 6, 2017

James Heller, chair of the firm's Products Liability Practice Group and vice chair of the Commercial Litigation Department, was quoted in *Law360*'s article, "\$28M Philly Xarelto Verdict Ripe For Reversal, Attys Say." After three prior bellwether trial losses, plaintiffs in litigation over the anticoagulant Xarelto are hoping to gain momentum following a \$27.8 million verdict in Philadelphia on Tuesday, but attorneys say the award faces an uncertain future thanks to testimony that additional warnings would not have changed a doctor's decision to prescribe the drug. Jim told *Law360* he doesn't believe the victory in Philadelphia will impact the bigger picture in Xarelto litigation given what he said were strong arguments against the verdict on post-trial motions and appeal. "If I were the defense, I would consider this a one-off," he said.

To read the full article, [click here](#).

Related Practice Areas

- Commercial Litigation
- Products Liability